These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG; Camm AJ Drugs; 1995 Aug; 50(2):250-62. PubMed ID: 8521758 [TBL] [Abstract][Full Text] [Related]
23. Propafenone: a novel type Ic antiarrhythmic agent. Parker RB; McCollam PL; Bauman JL DICP; 1989 Mar; 23(3):196-202. PubMed ID: 2655298 [TBL] [Abstract][Full Text] [Related]
24. Experimental evidence for beta adrenergic blocking properties of propafenone and for their potential clinical relevance. Malfatto G; Pessano P; Zaza A; Schwartz PJ Eur Heart J; 1993 Sep; 14(9):1253-7. PubMed ID: 7901020 [TBL] [Abstract][Full Text] [Related]
25. Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. Winslow E; Campbell JK; Barron E; Marshall RJ; Muir AW Br J Pharmacol; 1991 Dec; 104(4):853-8. PubMed ID: 1810599 [TBL] [Abstract][Full Text] [Related]
27. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog. Boucher M; Chassaing C; Hamel JD; Poirier JM Eur J Pharmacol; 1996 Nov; 315(2):171-7. PubMed ID: 8960881 [TBL] [Abstract][Full Text] [Related]
29. The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies. Reiffel JA; Blitzer M J Cardiovasc Pharmacol Ther; 2000 Jul; 5(3):177-81. PubMed ID: 11150406 [TBL] [Abstract][Full Text] [Related]
30. Sotalol: An important new antiarrhythmic. Anderson JL; Prystowsky EN Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618 [TBL] [Abstract][Full Text] [Related]
33. Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. Capucci A; Boriani G Drug Saf; 1995 Jan; 12(1):55-72. PubMed ID: 7741984 [TBL] [Abstract][Full Text] [Related]
34. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Suttorp MJ; Kingma JH; Jessurun ER; Lie-A-Huen L; van Hemel NM; Lie KI J Am Coll Cardiol; 1990 Dec; 16(7):1722-7. PubMed ID: 2123909 [TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacokinetics of the newer antiarrhythmic agents. Gillis AM; Kates RE Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721 [TBL] [Abstract][Full Text] [Related]
36. Electrophysiological effects of propafenone in untreated and propafenone-pretreated guinea-pig atrial and ventricular muscle fibres. Delgado C; Tamargo J; Tejerina T Br J Pharmacol; 1985 Dec; 86(4):765-75. PubMed ID: 4075015 [TBL] [Abstract][Full Text] [Related]
37. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Gillis AM; Verma A; Talajic M; Nattel S; Dorian P; Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862 [TBL] [Abstract][Full Text] [Related]
38. Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Boriani G; Martignani C; Biffi M; Capucci A; Branzi A Drugs; 2002; 62(3):415-23. PubMed ID: 11827557 [TBL] [Abstract][Full Text] [Related]
39. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. Lee JT; Kroemer HK; Silberstein DJ; Funck-Brentano C; Lineberry MD; Wood AJ; Roden DM; Woosley RL N Engl J Med; 1990 Jun; 322(25):1764-8. PubMed ID: 1971708 [TBL] [Abstract][Full Text] [Related]
40. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. Jazwinska-Tarnawska E; Orzechowska-Juzwenko K; Niewinski P; Rzemislawska Z; Loboz-Grudzien K; Dmochowska-Perz M; Slawin J Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]